The evolution of EBV DNA as a biomarker in nasopharyngeal carcinoma immunotherapy: a bibliometric and knowledge mapping analysis
Yang Chen, Qicong Chen, Xiaosu Zou, Wenqian Nong, Taicheng Lu, Sifang Xie, Weiming Deng, Min Li, Guiping Lan, Gang Wang, Shenhong Qu · 2026
Read The evolution of EBV DNA as a biomarker in nasopharyngeal carcinoma immunotherapy: a bibliometric and knowledge mapping analysis by Yang Chen, Qicong Chen, Xiaosu Zou, Wenqian Nong, Taicheng Lu, Sifang Xie, Weiming Deng, Min Li, Guiping Lan, Gang Wang, Shenhong Qu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13439843.txt.
Description
Yang Chen's team mapped research in 2026 on Epstein-Barr virus DNA as a biomarker for nasopharyngeal cancer immunotherapy. Response to immunotherapy varies widely, and viral DNA in blood tracks tumor biology, yet no full map of the field's growth and themes existed. One hundred sixty-four articles were analyzed for trends, countries, keywords, collaborations, and citations using bibliometric software.
Work surged after 2017, led by China and the United States, with hotspots around PD-1 drugs, tumor activity, and mechanisms, shifting from tumor burden and prognosis toward dynamic monitoring and trials. The paper frames viral DNA as a living biomarker joining virus, tumor load, and response. Oncologists get a field atlas for choosing monitoring strategies.
Catalog record
| CREATOR | Yang Chen, Qicong Chen, Xiaosu Zou, Wenqian Nong, Taicheng Lu, Sifang Xie, Weiming Deng, Min Li, Guiping Lan, Gang Wang, Shenhong Qu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |